PDF(Pubmed)
Abstract：
Organ transplantation is the gold standard therapy for end-stage organ failure. However, the shortage of available grafts and long-term graft dysfunction remain the primary barriers to organ transplantation. Exploring approaches to solve these issues is urgent, and CRISPR/Cas9-based transcriptome editing provides one potential solution. Furthermore, combining CRISPR/Cas9-based gene editing with an ex vivo organ perfusion system would enable pre-implantation transcriptome editing of grafts. How to determine effective intervention targets becomes a new problem. Fortunately, the advent of high-throughput CRISPR screening has dramatically accelerated the effective targets. This review summarizes the current advancements, utilization, and workflow of CRISPR screening in various immune and non-immune cells. It also discusses the ongoing applications of CRISPR/Cas-based gene editing in transplantation and the prospective applications of CRISPR screening in solid organ transplantation.
摘要：
器官移植是治疗终末期器官衰竭的金标准。然而,可用移植物的短缺和长期移植物功能障碍仍然是器官移植的主要障碍。迫切需要探索解决这些问题的方法，基于CRISPR/Cas9的转录组编辑提供了一个潜在的解决方案。此外，将基于CRISPR/Cas9的基因编辑与离体器官灌注系统相结合将能够实现移植物的植入前转录组编辑。如何确定有效的干预目标成为一个新问题。幸运的是,高通量CRISPR筛选的出现大大加快了有效靶标的速度.这篇综述总结了当前的进展，利用率，以及在各种免疫和非免疫细胞中进行CRISPR筛选的工作流程。它还讨论了基于CRISPR/Cas的基因编辑在移植中的持续应用以及CRISPR筛选在实体器官移植中的未来应用。
